Search the articles

Peptide Research in Neurological Disorders: Investigating the role of peptides being researched for conditions like Alzheimer’s and Parkinson’s

Introduction

            Peptides are essentially mini proteins – short chains of amino acids that are much smaller than typical proteins. Yet despite their small size, peptides can have powerful effects in the body. Our cells naturally use dozens of peptides as messengers and regulators, from hormones to growth factors. In simple terms, a peptide is a tiny biological signal that can tell cells what to do. Because of this, scientists can design or harness peptides to influence cell behavior in very specific ways.
            In neuroscience labs, peptides have become a hot topic. Why? Unlike conventional drugs, peptides can mimic the body’s own molecules and tap into innate healing pathways. They are being explored as precision tools to protect neurons, clear toxic proteins, and even cross the blood-brain barrier more easily than some larger therapies. For diseases like Alzheimer’s disease (AD) and Parkinson’s disease (PD), which involve complex brain changes, peptides offer a way to intervene that’s closer to the brain’s natural language.
            The urgency is high. Alzheimer’s – the most common dementia – slowly robs memory and identity from over 30 million people worldwide, yet current medications only ease symptoms and do not stop the relentless brain degeneration. Parkinson’s – a movement disorder affecting over 8 million people – is managed mainly by replacing dopamine (a brain chemical that dwindles in PD) to control tremors and stiffness. But nothing on the market today halts the underlying death of brain cells in Parkinson’s or Alzheimer’s. In short, both AD and PD have huge unmet needs: we need treatments that can slow or prevent the disease process, not just mask the symptoms. This is where peptide research comes in – offering fresh hope that these tiny molecules might do what standard drugs so far cannot.

Why Peptide Research Matters

            Peptides hold special promise for neurological disorders because of their unique abilities. First, many peptides can slip into places that larger molecules (like antibodies or proteins) can’t reach. Some experimental peptides have been engineered to cross the blood- brain barrier, meaning they can be delivered through the bloodstream or even the nose and still reach brain tissue. This is a big deal – it’s like finding a key to unlock the brain’s heavily guarded front door.
            Second, peptides can be incredibly specific in their actions. We can design a peptide to latch onto a precise protein or cell receptor, almost like a custom-shaped puzzle piece. This specificity means peptides can mimic the body’s own regulatory signals. For example, a peptide might activate a cell’s self-cleaning process or block a harmful interaction between two proteins, with a finesse that small chemical drugs often lack. It’s a bit like speaking the cell’s native language to correct its course, rather than shouting at it in a foreign tongue.
            Another advantage is that peptides are typically made of natural amino acids, so the body knows how to break them down. They tend to degrade into harmless byproducts (amino acids) and often cause fewer off-target side effects than synthetic drugs. In theory, this makes them safer messengers.
            In diseases like Alzheimer’s and Parkinson’s, which involve multiple things going wrong (toxic protein build-up, inflammation, loss of cell energy, etc.), peptides could tackle several problems at once. Some peptides have multifunctional effects – for instance, reducing brain inflammation and boosting cell energy production simultaneously. By acting more broadly (yet still specifically), a single peptide therapy might address the complex web of disease processes better than a one-trick chemical drug.
            Finally, peptide research is benefiting from cutting-edge technology. Scientists are using methods like CRISPR gene editing and high-throughput screening to discover new peptide candidates or improve existing ones. They are also developing clever delivery systems – such as nanoparticle carriers or nasal sprays – to get peptides safely into the brain. All these efforts underscore a simple point: peptides offer a fresh, biologically savvy approach to brain diseases that have been intractable for decades. They are not magic bullets, but they just might be the precision tools we need to finally slow diseases like AD and PD at their roots.

Peptide Spotlights

Let’s look at a selection of promising peptides being studied for Alzheimer’s, Parkinson’s, or both. Each of these experimental peptides works in a different way to protect the brain.

Here’s how they work and what early studies in the research have found:

Davunetide (NAP)
Davunetide, also known as NAP, is an 8–amino-acid peptide originally derived from a brain protein that supports neuron development. Davunetide became a candidate for Alzheimer’s and related disorders because it can stabilize microtubules – the inner “railroad tracks” of neurons that help transport nutrients and maintain cell structure. In diseases like AD (a tauopathy), those tracks break down when the tau protein that supports them goes haywire. Davunetide effectively acts like a microscopic track repair crew: it binds to microtubule- associated proteins and strengthens the microtubule network, so neurons don’t deteriorate as easily.
In animal studies of Alzheimer’s, davunetide has shown neuroprotective effects – for example, improving memory performance in rodents engineered to have Alzheimer-like symptoms. It also caught attention in a clinical trial for a rare dementia called PSP (progressive supranuclear palsy), which, like AD, involves toxic tau protein. That trial didn’t meet its main goals in the overall group, but intriguingly, a deeper analysis revealed that women on davunetide declined significantly slower than women on placebo, suggesting a real effect in a subgroup. This hint of benefit – along with davunetide’s ability to bolster neuronal structures – keeps it in the research spotlight as a potential therapy to slow cognitive decline. Davunetide has been tested in patients up to Phase II/III trials, but it is not an approved treatment. This peptide is available for research use only.

Humanin & S14G-Humanin
            Humanin is a remarkable peptide because it comes from an unexpected place: mitochondria (the energy-producing organelles inside cells). Discovered in 2001, humanin is a 24-amino-acid peptide encoded by mitochondrial DNA, and it appears to act as a built-in defense factor against cell stress. You can think of humanin as a “bodyguard” peptide – its job is to protect cells from threats like oxidative stress, protein clumping, and even gene mutations linked to Alzheimer’s. Notably, humanin was found to protect neurons from the toxicity of Alzheimer’s amyloid-beta (Aβ) peptides in lab experiments.
            Researchers created an even more potent version called S14G-humanin (also known as Humanin G), where one amino acid change makes it more effective. Humanin and its analogs work by activating survival pathways in cells. For instance, they can trigger the PI3K/AKT signaling route, which tells cells to ramp up protective processes like metabolism and autophagy (cellular garbage disposal). In plain language, humanin sends a “stay alive” signal to neurons under siege. It also improves how cells handle insulin, which is interesting because Alzheimer’s has been described as “diabetes of the brain” by some scientists.
            What have studies shown? In mice, humanin administration have been able to improve cognitive performance in aging – one study showed old mice performed better on memory tasks after humanin treatment, as if their brains had been rejuvenated. In cellular models of Alzheimer’s, humanin and S14G-humanin reduce amyloid accumulation and tau phosphorylation (a process that leads to tangles). Recently, a 2023 study delivered humanin intranasally in a Parkinson’s disease mouse model. The tiny peptide traveled along the olfactory and trigeminal nerve pathways directly into the brain. Once there, it boosted mitochondrial genes and energy production in neurons. The Parkinson’s mice treated with humanin had less neuron death and improved motor function, essentially protecting their dopamine-producing cells. It’s very much still in preclinical testing, but humanin exemplifies a naturally occurring neuroprotective peptide that we might harness as a therapy. This peptide is available for research use only.

Exendin-4 (GLP-1 Analogs)
            Exendin-4 may sound unfamiliar, but if you know someone with diabetes, you’ve likely heard of its modern incarnation: exenatide. Exendin-4 is a peptide originally isolated from Gila monster venom (yes, a lizard!), and it mimics a human hormone called GLP-1 (glucagon-like peptide-1). GLP-1 analogs like exenatide, liraglutide, and semaglutide are already used to treat type 2 diabetes by improving insulin release. So why are diabetes drugs being tested in Alzheimer’s and Parkinson’s? It turns out brain insulin signaling and energy use are impaired in these neurodegenerative diseases, and GLP-1 analogs have significant protective effects on neurons.
            Exendin-4 and other GLP-1 analogs bind to GLP-1 receptors in the brain, which sets off a cascade that enhances cell survival. They improve insulin sensitivity in neurons (important for memory and cell metabolism), reduce inflammation in the brain, and encourage the growth of new synapses (connections) between neurons. Think of GLP-1 analogs as a sort of metabolic booster and janitor combined: they help brain cells use energy more efficiently while cleaning up some of the toxic mess (such as misfolded proteins and inflammatory molecules) that accumulates with aging and disease. Another perk: these peptide drugs can cross into the brain from the bloodstream.
            In Alzheimer’s models, GLP-1 analogs have shown striking results. Rodent studies have found that treating Alzheimer’s mice with exendin-4 or liraglutide leads to less amyloid plaque buildup and less tau tangles, accompanied by sharper memory on maze tests. Essentially, the peptides appeared to slow the disease process in animals. In Parkinson’s, exenatide made headlines a few years ago when a small clinical trial in patients suggested improved motor function that persisted even after stopping the drug – something unprecedented, hinting at a possible disease-slowing effect. (A larger follow-up trial did not conclusively show disease progression slowing, but there were still signs of symptom improvement, so research continues.) The fact that several GLP-1 analogs are already approved for diabetes means we have safety data in humans and a fast track to repurpose them if efficacy is proven. Right now, multiple clinical trials are underway testing weekly injections of these peptides in early Parkinson’s and early Alzheimer’s. The hope is that by energizing cells and reducing toxic proteins, GLP-1 mimetics could serve as the first treatments to modify these diseases. This peptide is available for research use only.

Elamipretide (SS-31)
            Elamipretide (SS-31) is a mitochondria-targeted peptide that has researchers excited about shoring up the brain’s energy supply. Mitochondria, often called the cell’s “power plants,” are especially important in neurons – these cells are energy-hungry and when their mitochondria falter, neurons can die. Both Alzheimer’s and Parkinson’s involve mitochondrial dysfunction (imagine brownouts in a power grid), leading to energy shortfalls and oxidative damage in the brain. Elamipretide is designed to fix the power supply: it’s a four–amino-acid peptide that penetrates mitochondria and helps them work efficiently.
            How does it work? This peptide lodges in the inner mitochondrial membrane, where it binds to a lipid called cardiolipin that is crucial for mitochondrial structure and function. By doing so, elamipretide protects mitochondria from breaking apart (it inhibits excessive fission) and from leaking harmful reactive oxygen species. It also boosts the mitochondria’s ability to produce ATP (the cell’s energy currency) and can activate mitochondrial biogenesis (creation of new mitochondria) and mitophagy (removal of damaged mitochondria). In essence, elamipretide is like a combination electrician and mechanic for cellular power plants: it repairs the wiring, prevents meltdowns, and installs new equipment as needed.
            In preclinical studies, these actions translated into promising benefits. For example, in a mouse model of Parkinson’s, elamipretide protected the dopamine neurons from a toxin that would normally kill them, resulting in preservation of motor function. In Alzheimer’s models, cells treated with SS-31 had significantly less buildup of amyloid beta and less oxidative stress. One study in Alzheimer-like mice showed improved memory and synaptic function after a course of elamipretide injections, as if the neurons got a burst of newfound energy and resilience. Beyond animal models, elamipretide has undergone human trials for conditions like heart failure and rare mitochondrial diseases, suggesting it’s generally safe and can reach tissues effectively. It has not yet been tested in AD or PD patients but given the common theme of mitochondrial trouble in those diseases, researchers see a lot of potential. By keeping neurons’ “lights on” and reducing their exposure to damaging free radicals, elamipretide might slow the cascade of cell death in neurodegeneration. It remains at the experimental stage for now. This peptide is available for research use only.

NPT200-11 and Other α-Synuclein-Interfering Peptides
            One of the central villains in Parkinson’s disease is a misbehaving protein called alpha- synuclein (α-syn). In healthy brains, α-synuclein likely helps with neurotransmitter release, but in Parkinson’s it starts clumping into toxic aggregates that damage neurons. Stopping α-synuclein from aggregating is a huge focus in PD research. NPT200-11 is a leading compound in that effort – a small molecule (not a peptide itself, despite the name) that was developed to bind α- synuclein and prevent it from misfolding into harmful shapes. We include it here because it’s often discussed alongside peptide-based strategies targeting α-syn. Essentially, NPT200-11 acts like molecular glue that sticks to α-synuclein monomers and blocks them from stacking into oligomers and fibers.
            In PD model mice overproducing human α-synuclein, NPT200-11 showed multiple benefits: it reduced the load of α-synuclein aggregates in the brain, calmed down neuroinflammation (less activation of the brain’s immune cells), and even normalized levels of dopamine transporter – a key protein needed for dopamine neuron function that is usually lost in Parkinson’s. Impressively, these changes translated into better movement ability in the treated mice. This compound was able to enter the brain when given orally and was well-tolerated in initial human safety trials (Phase I). While NPT200-11 itself is a small molecule, it represents a broader strategy of intercepting toxic proteins with precision-designed agents, including peptides.
            In fact, scientists are also developing peptide-based therapies to tackle α-synuclein. One innovative example is a “knockdown” peptide called Tat-βsyn-degron. This is an engineered peptide that can enter neurons (thanks to a Tat protein fragment for cell entry) and then attach to α-synuclein and mark it for destruction by the cell’s own garbage disposal (the proteasome). In rodent models of Parkinson’s, the Tat-βsyn-degron peptide drastically lowered α-synuclein levels and protected dopamine neurons from dying. Treated Parkinson’s-model mice showed improvements in motor function, as the toxic protein clog was cleared out of their neurons. This approach is like sending in a special ops cleanup crew that finds the problematic protein and tags it with a “destroy me” label. Early results are very promising in labs, though it’s still a long road to human trials.
            Whether by preventing protein misfolding (like NPT200-11) or by accelerating protein cleanup (like the degron peptide), these strategies aim to directly neutralize the root cause of Parkinson’s pathology. They could be truly disease-modifying if successful. Several are in preclinical development, and at least one (NPT200-11’s successor) has reached Phase 2 trials in patients. It’s an exciting time for this targeted approach, but it’s important to note none have proven themselves in clinical efficacy yet. This peptide is available for research use only.

P110
            While some peptides fight bad actors like amyloid or α-synuclein, P110 takes a different tactic: it protects neurons by preserving the health of their mitochondria through regulating mitochondrial dynamics. P110 is a short peptide that selectively inhibits a protein called Drp1 from excessively chopping up mitochondria. Why is that important? In stressed or diseased neurons, Drp1 can become overactive and cause mitochondrial fragmentation – basically breaking the energy-producing organelles into tiny dysfunctional bits. This fragmentation contributes to neuronal death in conditions ranging from Parkinson’s to Alzheimer’s (and even stroke and ALS). P110 swoops in to block Drp1’s interaction with a receptor (Fis1) that triggers this excessive fission, without disturbing Drp1’s normal functions in healthy cells.
            Picture mitochondria as long, interconnected power cables in a cell. In neurodegeneration, these cables start getting cut into shreds. P110 is like an emergency circuit breaker that stops the frenzied cutting, keeping mitochondrial networks intact. In experimental models, the effects of P110 have been impressive. In cell cultures exposed to Parkinsonian toxins, P110 preserved mitochondrial shape and prevented the cascade of cell death that would normally occur. Neurons treated with P110 had lower levels of reactive oxygen species and maintained their ATP production better under stress. In animal models, P110 has shown protective benefits as well – for example, improving motor function in mice where Parkinson-like neurodegeneration was induced, and even extending survival in some models of ALS. By halting the mitochondrial breakdown, P110 indirectly reduces oxidative damage, inflammation, and the activation of cell death pathways that follow in the wake of mitochondrial failure.
            It’s worth noting that P110 itself is used as a research tool (peptides like this don’t always make practical drugs because they might not last long in the body). However, the insights gained led scientists to develop drug-like molecules mimicking P110’s action. The key takeaway is that keeping mitochondria healthy and balanced is a viable strategy to slow neurodegeneration, and P110 proved that concept. In the lab, it rescues neurons in multiple disease models without noticeable toxicity. It exemplifies a neuroprotective peptide approach aimed at the cell’s infrastructure rather than the usual suspects of amyloid or alpha-syn. While not in clinical use, P110 has opened doors to new therapies targeting mitochondrial stability. This peptide is available for research use only.

Selank
            Not all brain-active peptides target specific disease proteins; some boost the brain’s resilience and cognitive function more broadly. Selank is one such peptide. It’s a synthetic variant of an immune system peptide called tuftsin, originally developed in Russia as an anti- anxiety medication. Selank has been shown to produce a calming effect (by modulating GABA receptors in the brain) and at the same time enhance learning and memory in animal studies. This dual action – anxiolytic and nootropic – makes Selank intriguing for conditions like age- related cognitive decline or even Alzheimer’s, where anxiety and cognitive impairment often go together.
            Mechanistically, Selank does a few things that could be beneficial in neurodegeneration. It increases the levels of brain-derived neurotrophic factors (BDNF), a key protein that supports neuron growth and survival and is crucial for memory formation. Low BDNF is associated with Alzheimer’s progression, so raising it is generally positive. Selank also modulates immune responses and may reduce certain inflammatory cytokines in the brain (since it’s based on an immune peptide). In a sense, Selank is like a gentle brain tune-up: reducing stress signals and inflammation while promoting factors that underline neural plasticity.
            Studies in rats have shown that Selank can improve memory retention and prevent cognitive damage under stressful conditions. For example, in one experiment, rats exposed to chronic alcohol (which usually harms memory and lowers BDNF) were given Selank. The treated rats performed better on memory tasks and did not show the drop in BDNF that the untreated ones did. This suggests Selank protected their brains from alcohol-induced injury. Such neuroprotective effects, along with its anti-anxiety properties, have led some to propose Selank as an adjunctive therapy for cognitive disorders or after brain injuries. It’s important to note that most Selank research has been in preclinical or early clinical stages, and it hasn’t been evaluated in large trials for Alzheimer’s or Parkinson’s. Still, it represents a class of regulatory peptides that enhance the brain’s own repair and adaptation mechanisms. Selank is legally used in a few countries for anxiety, but elsewhere it’s still an experimental compound when it comes to cognition. This peptide is available for research use only.

CN-105
            CN-105 is a tiny peptide (just 5 amino acids long) derived from a segment of the APOE protein. APOE might sound familiar – it’s the gene with variants like APOE4 that dramatically affect Alzheimer’s risk. The idea behind CN-105 is to capture some of the beneficial properties of the “good” APOE variants in a short peptide that could be used as a drug. APOE does many things in the brain, including helping clear out amyloid-beta and modulating inflammation. CN- 105 was engineered as an ApoE-mimicking peptide that is much smaller than the full protein but can penetrate the brain and calm neuroinflammation.
            In preclinical models of Alzheimer’s disease, CN-105 has shown encouraging results. Researchers found that treating AD-model mice with CN-105 reduced the buildup of amyloid plaques and rescued some of the memory deficits. It appears CN-105 can bind to amyloid-beta and prevent it from aggregating, as well as promote its clearance by microglia (the brain’s immune cells). Additionally, CN-105 has strong anti-inflammatory effects – it dampens the overactivation of microglia and astrocytes that is thought to exacerbate Alzheimer’s pathology. In essence, CN-105 tackles two core issues: it helps remove toxic amyloid and protects the brain from collateral damage due to inflammation.
            Interestingly, CN-105 has also been tested in models of brain injury and stroke, where inflammation is a major culprit. For example, in animal models of hemorrhagic stroke, CN-105 reduced brain swelling and improved neurological recovery, likely by the same calming effect on immune responses. A Phase 1 clinical trial in humans (in patients with hemorrhagic stroke) indicated that CN-105 was safe and able to enter the cerebrospinal fluid. This bodes well for its development, since it shows the peptide can reach the central nervous system when administered systemically. While not yet tested in Alzheimer’s patients, CN-105 holds promise as a dual-action therapeutic: part amyloid-clearance agent, part neuroinflammation modulator. It’s like a two-pronged shield protecting the brain’s environment. More research will determine if those mouse memory improvements can translate to human benefits. For now, CN-105 remains in the investigative stage. This peptide is available for research use only.

RD2 and Aβ-Clearing Peptides
            One of the boldest peptide strategies for Alzheimer’s is to directly attack the plaques and soluble aggregates of amyloid-beta in the brain. Instead of using antibodies (like several current drugs do) or small molecules, researchers have developed peptides that bind to Aβ and prevent it from clumping or even break existing clumps apart. An outstanding example is RD2, a peptide consisting entirely of D-amino acids (mirror-image forms of natural amino acids). Using D-amino acids makes the peptide resistant to degradation in the body, so it can survive long enough to do its job.
            RD2 was designed to latch onto the toxic Aβ oligomers – the small clusters of amyloids that are particularly harmful to neurons – and neutralize them. In an impressive study, very old transgenic mice with advanced Alzheimer-like pathology were treated with RD2 orally. The results were nothing short of remarkable: RD2 not only stopped further cognitive decline, but it also actually improved the mice’s memory performance and significantly reduced the load of Aβ plaques and oligomers in their brains. In other words, this peptide appeared to reverse some aspects of the disease in animals that already had severe symptoms. It’s as if RD2 acted as a molecular solvent for amyloid gunk, clearing out the synapse-clogging aggregates and giving neurons a second chance.
            Another peptide called D3 (an earlier version of RD2) similarly showed the ability to dissolve pre-formed amyloid fibrils in lab tests. These peptides basically take the stickiness out of Aβ, rendering it non-toxic. The advantage of a peptide approach here is that the molecules are small enough to diffuse through brain tissue and reach plaques, and if made of D-amino acids, they are not quickly broken down by enzymes. RD2 has been taken into early-phase human studies by researchers in Germany, though it’s still a long way from any clinical use. It represents a exciting principle: that even entrenched protein aggregates in the brain might be disassembled with the right key, in this case a peptide key. Should this approach succeed, it could improve cognition by removing the source of neural dysfunction (rather than just slowing down new damage). For now, it’s a trailblazing research avenue. This peptide is available for research use only.

Future Directions & Research Gaps
As peptide research for neurodegenerative diseases accelerates, scientists are also addressing challenges and exploring new frontiers to make these therapies more effective:

CRISPR-Aided Peptide Design: The gene-editing tool CRISPR is not only a potential therapy, but also a powerful laboratory aid for peptide research. Scientists can use CRISPR to create cell and animal models of Alzheimer’s or Parkinson’s that incorporate “reporter” genes, allowing them to screen large libraries of candidate peptides quickly for any that rescue cell health. CRISPR can also help insert peptide-coding sequences directly into the genomes of model organisms, essentially turning the organism’s own cells into peptide factories. This way, researchers can observe long-term effects of peptide production and fine-tune peptide sequences in living systems. In the future, one could imagine using CRISPR to activate a dormant neuroprotective peptide gene in a patient’s brain – a form of gene therapy that delivers a beneficial peptide on-site. We are just scratching the surface of such possibilities, but CRISPR is speeding up the discovery and optimization of therapeutic peptides in the lab right now.
Intranasal Peptide Delivery: One practical hurdle for peptide drugs is getting them into the brain in sufficient amounts. Many peptides can’t be given as pills because they’d be digested in the stomach. Injections work, but a peptide in the bloodstream still faces the blood-brain barrier. An ingenious solution being tested is intranasal delivery – essentially, a nasal spray. The nose has direct neural connections to the brain (olfactory and trigeminal pathways), providing a possible highway for molecules to travel into the CNS. We saw this used successfully in animal studies (for example, humanin was delivered intranasally to reach the brain in a PD mouse model). Intranasal formulations of peptides like oxytocin and insulin have already been tried in humans for other conditions, showing that the method is feasible and patient friendly. For Alzheimer’s and Parkinson’s peptides, intranasal delivery could be a game-changer: imagine a future where a patient simply sprays a neuroprotective peptide into their nose daily as a prevention measure. This route avoids dilution in the whole bloodstream and directly targets the brain with potentially fewer side effects. Research is ongoing to improve intranasal absorption and distribution – for instance, using nanoparticle carriers or gel formulations to enhance contact in the nasal cavity. The goal is to achieve reliable, non- invasive brain delivery so that peptide therapies are convenient and effective.
Multi-Target Hybrid Peptides: Alzheimer’s and Parkinson’s are multifactorial diseases – there isn’t just one thing going wrong. The current trend is to design hybrid peptides that combine two or more functional domains in one molecule to address multiple targets at once. We can liken this to a Swiss Army knife approach, versus having a bunch of single-function tools. An exciting example comes from a recent study where researchers fused two peptides we discussed: they took S14G-humanin (which protects mitochondria and cells) and SS-31 (which targets mitochondria and fights oxidative stress) and merged them into one hybrid peptide. This new peptide, dubbed HNSS, not only had dual action – boosting mitochondrial function and blocking amyloid toxicity – but its structure was tweaked to improve penetration into the brain. In Alzheimer’s model mice, the hybrid peptide HNSS was more effective than either component alone: it improved cognitive function, reduced amyloid deposition, and reduced neuron loss. This proof-of- concept opens the door to custom-made peptide chimeras: for instance, a single peptide that could simultaneously clear amyloid, suppress inflammation, and promote neuron growth. The challenge is designing such multi-functional peptides that are still stable and safe, but advances in computer-aided design and peptide engineering are making this possible. Hybrid peptides could tackle the complex disease pathways of AD/PD in a coordinated way, potentially yielding a stronger therapeutic effect than hitting one target at a time.

Conclusion

Peptides represent a new wave of potential treatments that could change the narrative for Alzheimer’s and Parkinson’s diseases. They are versatile molecules – able to slip into the brain, speak the cell’s biochemical language, and address the nuanced problems that drive neurodegeneration. From reinforcing the cell’s infrastructure (mitochondria and microtubules) to clearing out toxic aggregates and soothing inflammation, these tiny proteins are proving in labs that they can do things traditional drugs have struggled to achieve. The stories of peptides like humanin, davunetide, and others offer a glimpse of a future in which we might slow or even prevent the loss of brain function by intervening early and multitasking therapeutically. Peptides are exciting tools in clinical trials and laboratory experiments.